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Abstract: 3-Nitro-1H-1,2,4-triazole- and 2-nitro-1H-imidazole-based amides with an aryloxy-
phenyl core were synthesized and evaluated as antitrypanosomal agents. All 3-nitrotriazole-
based derivatives were extremely potent anti-T. cruzi agents at sub nM concentrations and 
exhibited a high degree of selectivity for the parasite. The 2-nitroimidazole analogs were only 
moderately active against T. cruzi amastigotes and exhibited low selectivity. Both types of 
compound were active against L. donovani axenic amastigotes with excellent selectivity for the 
parasite, whereas three 2-nitroimidazole-based analogs were also moderately active against 
infected macrophages. However, no compound demonstrated selective activity against T.b. 
rhodesiense. The most potent in vitro anti-T. cruzi compounds were tested in an acute murine 
model and reduced the parasites to an undetectable level after five days of treatment at 13 
mg/kg/day. Such compounds are potential inhibitors of T. cruzi CYP51 and, being excellent 
substrates for the type I nitroreductase (NTR) which is specific to trypanosomatids, work as 
prodrugs and constitute a new generation of effective and more affordable antitrypanosomal 
agents.  
Key words: nitrotriazoles; nitroimidazoles; type I nitroreductase; antitrypanosomal agents; 
Chagas disease; L. donovani 
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Parasitic infections caused by trypanosomatids constitute a major health problem in mainly 
resource poor countries around the world and diseases acquired by such infections are considered 
‘neglected’ because they have received limited funding for discovery, development and delivery 
of new treatments. Amongst neglected tropical diseases (NTD)
1
, human African trypanosomiasis 
(HAT; caused by T. b. rhodesiense and T. b. gambiense) is endemic throughout sub-Saharan 
Africa while American trypanosomiasis (Chagas disease; caused by T. cruzi) affects populations 
in South and Central America. In contrast, leishmaniasis (caused by Leishmania species) is 
prevalent in many sub-tropical and tropical regions of the World [1]. It is estimated that together 
these three insect transmitted diseases are responsible for more than 110,000 deaths per year [2]. 
Although the incidence of T. cruzi infection has significantly declined recently due to 
implementation of vector control initiatives, the number of cases in non-endemic sites (United 
States, Australia, Europe and Japan) is rising, primarily due to international population migration 
and contaminated blood transfusions [3,4].  
The treatment of neglected diseases is based on pharmaceuticals with poor efficacy, 
significant side effects, high cost, poor oral bioavailability requiring a parenteral administration, 
long treatment course and emergence of resistance. Thus, severe toxicity and long treatment 
requirements coupled with limited efficacy are associated with nifurtimox (Nfx) and 
benznidazole (Bnz), the two currently used medications for Chagas disease [5, 6]. Similarly, 
drugs used to treat HAT and leishmaniasis are highly toxic (e.g. melarsoprol, antimonials), or 
require i.v. administration (e.g. melarsoprol, suramin, DFMO, antimonials) resulting in severe 
side effects, or are of high cost (e.g. DFMO, liposomal amphotericin B, miltefosine, and 
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paromomycin) [7-9]. Therefore, new effective, safe and affordable drugs are urgently needed for 
the treatment of these neglected diseases. 
Inhibitors of the fungal sterol 14-demethylase enzyme (CYP51) and currently inhibitors of 
the orthologous enzyme T. cruzi CYP51 (TcCYP51) have demonstrated promising efficacy 
against Chagas disease in preclinical studies [10-15]. However, in patients with chronic Chagas 
disease, the antifungal agent posaconazole was shown to be inferior to Bnz based on qPCR 
detection of T. cruzi DNA, measured 10 months after the end of treatment [16].  Moreover, in 
newly designed in vitro assays, nitroheterocyclic compounds were more efficacious trypanocidal 
agents compared to CYP51 inhibitors [17], and in an acute murine infection model with Bnz and 
posaconazole administered concomitantly or in sequence, a positive interaction was observed 
between the two drugs [18].
 
These data suggest that inhibitors of sterol biosynthesis may not be 
as efficient as single chemotherapeutic agents against Chagas disease as they are against fungal 
infections, but they may be effective in combination with known or new nitroheterocyclic 
antichagasic agents. However, combining agents in vivo cannot always be effective due to 
differential pharmacokinetic behavior of each drug, failure to obtain an optimal required 
concentration and possible unexpected adverse effects. Combining CYP51 inhibition 
characteristics with bioreduction properties of a nitro-group in one molecule may offer a better 
solution in drug development against Chagas disease and other trypanosomatid-induced diseases. 
This strategy has been successfully used in numerous occasions, including drugs for cancer, 
asthma and chronic obstructive pulmonary disease as well as neurodegenerative diseases [19-22].  
We have demonstrated that a variety of 3-nitro-1H-1,2,4-triazole-based compounds exhibit 
excellent anti-T. cruzi activity both in vitro and in vivo, with several analogs also showing 
appreciable anti-T. b. rhodesiense activity in vitro [23-27]. Interestingly, 3-nitrotriazole-based 
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compounds are significantly more potent and less toxic than their 2-nitroimidazole-based 
counterparts [23-27], 
 
with part of the trypanocidal activity being dependent on the parasite’s 
expression of an oxygen-insensitive type I nitroreductase (NTR), an enzyme absent from most 
other eukaryotes [23, 24, 26, 27]. Type I NTR, via a series of 2 electron reduction reactions 
which lead to the production of toxic metabolites, is responsible for the trypanocidal activity of 
Nfx, Bnz and other nitroheterocyclic  prodrugs in general [29-32]. More recently, we have 
developed 3-nitrotriazole-based amides with a linear, rigid core, as well as 3-nitrotriazole-based 
carbinols (fluconazole analogs) which, in addition to being substrates for type I NTR, are also 
inhibitors of TcCYP51 [33]. These bifunctional agents exhibit promising anti-T. cruzi activity in 
vitro and in vivo and have excellent ADMET characteristics [33]. 
In the current work we have expanded our search for more potent bifunctional antichagasic 
agents by investigating the role of an aryloxy-group in the scaffold of 3-nitrotriazole-based linear 
amides. Imidazole-based inhibitors of TcCYP51 with an aryloxy group in their scaffold have 
been previously identified [15]. Therefore, we hypothesized that 3-nitrotriazole-based analogs 
could potentially be inhibitors of this enzyme, in addition to their capacity of being substrates of 
type I NTRs.  
 
2. Results and Discussion 
2.1. Chemistry 
The structures of synthesized compounds are shown in Table 1. Their synthesis is 
straightforward, based on well-established chemistry and outlined in Scheme 1. Thus, amides 2-
14 were obtained by nucleophilic substitution of the appropriate chloroacetamides 1a-h with the 
potassium salt of 3-nitro-1,2,4-triazole, 2-nitroimidazole or 1,2,4-triazole under refluxing 
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conditions. Chloroacetamides 1a-h were prepared from appropriate, commercially available 
aryl/alkylamines and chloroacetyl chloride in the presence of triethylamine at room temperature. 





T.b. rhodesiense, strain STIB 900 trypomastigotes; 
b
 T. cruzi, strain Tulahuen C4 amastigotes; 
c
 
L. donovani axenic, strain MHOM-ET-67/L82 amastigotes; 
d
Cytotoxicity in the host L6 cells. SI 
is the ratio: IC50 in L6 cells/IC50 in each parasite. The highest concentration tested in L6 cells 
was 100 μg/mL and no solubility problems were observed for any compound. Reference drugs: 
Melarsoprol (Melar.), Benznidazole (Bnz), Miltefosine (Milt.). The IC50 value of each reference 
drug is the mean from multiple measurements in parallel with the compounds of interest. 
Bnz/comp is the ratio of IC50 values against T. cruzi obtained by Bnz and each compound. PSA: 
polar surface area. All physical properties were predicted by using the Marvin Calculator 
(www.chemaxon.com). IC50 values are means of 2 to 3 measurements. The SD was < 5%. 
 





2.2. Biological Evaluation 
2.2.1. Anti-parasitic activity  
Compounds on Table 1 were screened for anti-parasitic activity against three trypanosomatids: T. 
cruzi, T. b. rhodesiense and Leishmania donovani. The concentration of compound that inhibits 
parasite growth by 50 % (IC50) was calculated from dose response curves for each parasite 
(Table 1). Compounds were also tested for toxicity in L6 rat skeletal myoblasts, the host cells for 
T. cruzi amastigotes, in order to calculate a selectivity index for each parasite (SI = 
IC50L6/IC50parasite) (Table 1). According to the TDR (Special Programme for Research and Training 
in Tropical Diseases, World Health Organization) criteria for antiparasitic activity and 
selectivity, an IC50 of <4.0 µM, between 4.0-60 µM or >60 µM, designates ‘active’, ‘moderately 
active’ or ‘inactive’ compounds, respectively, against T. cruzi amastigotes, while a SI of ≥50 is 
required; for blood stream form (BSF) T. b. rhodesiense, IC50 values of <0.5 µM, between 0.5-
6.0 µM or > 6.0 µM identify ‘active’, ‘moderately active’ or ‘inactive’ compounds, respectively, 
while a SI value of ≥100 is desired; finally, for L. donovani amastigotes, IC50  of <1 µM, between 1.0-
6.0 µM or > 6.0 µM, provides ‘active’, ‘moderately active’ or ‘inactive’ compounds, respectively, 
whereas a SI value of ≥20 is ideal [34].  
According to the criteria described above, all 3-nitrotriazole-based analogs, except 11, were 
selectively active against T. cruzi amastigotes, whereas the 2-nitroimidazole-based analogs 12-
14, although active against T. cruzi, exhibited unacceptable SI values (Table 1). Compound 5, 
the des-nitro analog of 3, was moderately active against T. cruzi but was also not selective 
against the parasite. 
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Several 3-nitrotriazole-based compounds (2-4, 6, 9, 10) and one 2-nitro-imidazole-based 
analog (13) were moderately active against T. b. rhodesiense, however, only the chloro-
biphenylamide 6 demonstrated an acceptable selectivity for this parasite (Table 1). 
Interestingly and, for the first time, both 3-nitrotriazole-based- and 2-nitroimidazole-based 
analogs demonstrated a remarkable and selective activity against L. donovani amastigotes (Table 
1). Thus, only the des-nitro analog of 3, namely compound 5, the phenylpyrimidinylacetamide  8 
and the N-benzylpiperidine-amide 11 weren’t active against L. donovani.   
 
2.2.2. SAR analysis of antichagasic activity 
The unsubstituted 3-nitrotriazole-based aryloxy-phenylamide 2 was a very potent anti-T. cruzi 
agent displaying an IC50 of 65 nM against this parasite, 31-fold lower than that observed using 
Bnz, and having a SI of 1416.  When a p-chloro group was introduced in the terminal phenyl of 
2, the anti-T. cruzi potency increased by 8-fold and the SI by 2.6 in analog 3. Therefore, 
compound 3 was 254-fold more active than Bnz, and represents the most potent analog in this 
series. This increase in potency may be related to the increased lipophilicity of 3 compared to 2 
(Table 1). However, the presence of the nitro-group was far more important for activity than 
lipophilicity. Therefore, the des-nitro analog of 3, compound 5, albeit more lipophilic than 3, was 
only moderately active against T. cruzi, while its increased lipophilicity resulted in an 
unfavorable SI (<50). The fact that compound 5 demonstrated moderate activity against T. cruzi 
also indicates an alternative mechanism of action, independent of nitroreduction. 
The fluoro-analog of 3, compound 4, was also more potent against T. cruzi than the 
unsubstituted compound 2, with an IC50 value of 36 nM and a SI of 1954. However, 4 was 4.5- 
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fold less potent than 3, presumably due to its lower lipophilicity, but still 56-fold more potent 
than Bnz (Table 1). 
To better understand the role that the ether link in 3 plays in mediating anti-T. cruzi activity, 
we included some biphenyl/biaryl compounds in the study. The biphenyl compound 6 has been 
described before by our group [33]. Compound 6, which shares a similar lipophilicity with its 
aryloxy-analog 3, was also very potent and selective against T. cruzi, however its potency was 
ca. 5.6- fold lower than that of 3, signifying the importance of the ether link in the core of these 
compounds for anti-T. cruzi activity. Similarly, the biphenyl compound 7 was about 2.8-fold less 
potent against T. cruzi compared to the unsubstituted aryloxy-compound 2 and 4-fold less potent 
than 6. In the latter case the drop in activity of 7 may be related to its significantly lower 
lipophilicity compared to 6 rather than the meta-position of the terminal phenyl group.  
When the second phenyl ring in 7 was replaced with a pyrimidine ring in 8, the anti-T. cruzi 
activity was reduced by a factor of 14, despite the fact that both 7 and 8 share a similar clogP 
value. However, a greater PSA value in 8 may negatively affect permeability and thus activity 
[35]. 
Replacing the phenoxy-group of 2 with a benzyl-group in 9 did not affect anti-T. cruzi 
activity. However, the SI of 9 was reduced >2.5, due to higher toxicity in host cells and was 
independent of lipophilicity since both compounds share a similar clogP value (Table 1). 
Inserting an oxygen in 9 to obtain the benzyloxy-analog 10 increased anti-T. cruzi activity and 
selectivity compared to both analog compounds 9 and 2, consistent with an increase in the 
lipophilicity of 10. In addition, 10 was about 2-fold less toxic than 9, presumably due to its 
slightly greater PSA value which may decrease permeability [35]. Furthermore, when the 
anilino-ring of 9 was replaced with a 4-piperidine-amino ring in 11, disturbance in the planarity 
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decreased significantly the activity against T. cruzi, resulting in an IC50 of 8 μM and an 
unacceptable SI of ca. 14 for compound 11.   
For comparison purposes we have synthesized and evaluated the anti-T. cruzi activity of 2-
nitroimidazole-based aryloxy-phenyl amides 12-14, analogs of 2-4, respectively. Although 
compounds 12-14 were more lipophilic than their 3-nitrotriazole-based analogs 2-4, they 
demonstrated significantly less activity (65- to 324-fold) against T. cruzi. In addition, albeit 
compounds 12-14 were active/moderately active according to the TDR criteria, they 
demonstrated an unfavorable SI, confirming again the superiority of the 3-nitrotriazole- versus 
the 2-nitroimidazole ring against T. cruzi. From the above discussion it is concluded that a 3-
nitrotriazole ring coupled with a aryloxy-phenyl core is important for potent antichagasic  
activity and superior selectivity. With the exception of compound 8, there was also a good 
correlation between anti-T. cruzi activity and lipophilicity among the 3-nitrotriazole-based 
analogs. Thus, antichagasic activity increased with increasing clogP value (Fig.1s in 
supplementary material). Good correlation also existed between lipophilicity and antichagasic 
activity in the 2-nitroimidazole-based analogs, although the limited number of analogs does not 
allow definitive conclusions.  
 
2.2.3. SAR analysis of anti-T. brucei activity 
Moderate activity was observed against BSF of T. b. rhodesiense with several analogs (2-4, 6, 9, 
10, 13). Only the 3-nitrotriazole-based biphenylamide 6, however, demonstrated an acceptable 
selectivity (>100). Interestingly, there was relatively good correlation between anti-T. cruzi and 
anti-T. b. rhodesiense activity (R
2
 = 0.77) among nitrotriazoles active against both parasites (Fig. 
2s in supplementary material), something that was not observed before with other 3-nitrotriazole-
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based scaffolds [23-25, 33]. Thus, anti-T. b. rhodesiense activity (similarly to anti-T. cruzi 
activity) increased as the clogP increased with chloro-substitution enhancing potency in 
comparison to fluoro- or no-substitution (compare 2, 3 and 4 in the 3-nitrotriazole-based 
subgroup, and compare 12, 13 and 14 in the 2-nitroimidazole-based subgroup). Although there 
was relatively good correlation between T. cruzi and T. b. rhodesiense IC50 values for the diaryl 
derivatives 6-8 (R
2
=0.87), the 3-biphenyamide 7 was inactive against T. b. rhodesiense, in 
contrast to its 4-biphenyl analog 6, which displayed moderate activity and selectivity. Similarly, 
the 4-phenyl-pyrimidine amide 8 was inactive against T. b. rhodesiense.  Once again, the des-
nitro analog of 3, compound 5, was deemed “inactive” against T. b. rhodesiense based on the 
TDR criteria, although the trypanocidal effect it did display made it more potent than the nitro-
compounds 7 and 8, suggesting that the latter two may not be such good substrates for TbNTR. 
 
2.2.4. SAR analysis of anti-L. donovani activity 
This is the first report of 3-nitrotriazole- and 2-nitroimidazole-based compounds demonstrating 
selective anti-L. donovani activity. If we consider the active/moderately active 3-nitrotriazole-
based analogs with the exception of 10, there was a relatively good correlation between anti-T. 
cruzi and anti-L. donovani activity (R
2
 = 0.82), whereas in the case of compounds with better 
structural similarity we observe an even better correlation, although the number of analogs in 
these cases is inadequate for correlations. In addition, increasing lipophilicity resulted in an 
increased anti-L. donovani activity (Table 1). Chloro-substitution was more beneficial for 
activity than fluoro- or no substitution (compare 2, 3 and 4, as well as 12-14). The ether link in 
the core was more beneficial for activity than the methylene- or methylenoxy-link (2 vs 9 and 10) 
or no link at all (3 vs 6). Disturbance in the planarity of the core in 11, or deletion of the nitro 
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group in 5, abolished anti-L. donovani activity. Similarly, replacement of the middle phenyl ring 
in 7 with a pyrimidine ring in 8, resulted in abolishment of the anti-L. donovani activity (Table 
1). Two 3-nitrotriazoles (4 and 6) and one 2-nitroimidazole (13) demonstrated similar activity to 
the reference compound miltefosine, whereas the 3-nitrotriazole-based p-chlorophenyloxyphenyl 
amide 3 was ca. 4.8-fold more potent than miltefosine, with a SI of 853. Compounds 2, 12 and 
14 were selectively active against this parasite at nM concentrations, but slightly less potent than 
miltefosine. Finally, compounds 7, 9 and 10 were moderately active and with acceptable 
selectivity against the parasite (Table 1). If we compare the corresponding 3-nitrotriazole-based 
and 2-nitroimidazole-based analogs, the former were 1.6 to 4-fold more active than the latter 
against L. donovani parasites (2 vs 12, 3 vs 13 and 4 vs 14).  
 
Table 2. Antileishmanial activity and toxicity in infected macrophages 
 





Activity  in 






Milt. 0.162  ± 0.017 6.894
2 0.27 339 >30 89 0.60
3 0.034 853 >27 80 4.8
4 0.18 384 >28 84 0.89
6 0.17 738 >84 >84 0.95
9 1.2 31 >30 >89 0.12
12 0.79 79 16 >89 0.21
13 0.14 937 15 >81 1.2
14 0.29 418 14 >84 0.55
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Compounds with substantial selective activity against L. donovani axenic amastigotes were 
also tested for activity and toxicity in infected macrophages, a model more suitable for drug 
screening (36), since it takes into account host cell-mediated effects (Table 2). Despite activity 
against L. donvani axenic amastigotes, the 3-nitrotriazole-based analogs (2-4, 6 and 9) were not 
particularly active in infected macrophages, whereas the 2-nitroimidazole-based analogs (12-14) 
demonstrated moderate activity (IC50 <20 μM) in this assay. Reduced intracellular activity might 
be associated with metabolic stability of the compounds in the macrophages or permeability 
issues, although permeability studies through Caco-2 cells with some analogs did not indicate 
any permeability problems.   
 
2.2.5. Involvement of type I Nitroreductase  
Representative analogs from Table 1 were evaluated as substrates of purified, recombinant 
trypanosomal NTRs and compared to benznidazole (Table 3). Enzyme specific activity was 
measured as oxidized NADH per min per mg of protein. All tested compounds were excellent 
substrates of both TcNTR and TbNTR and metabolized by the T. cruzi enzyme at rates 
comparable or better than that of Bnz. However, the same analogs were metabolized by TbNTR 
at rates 1.6 to 2.2-fold higher than that of Bnz (Table 3). When these studies were extended to 
investigate the role of NTR within the parasite itself, BSF T. b. brucei was used and induced to 
express elevated levels of TbNTR. T. b. brucei is the model organism for all three sub-species (T. 
b. rhodesiense, T. brucei gambiense and T. b. brucei) and can be handled in a level 2 
containment lab (with appropriate clearance from Ministry of Agriculture) whereas T. b. 
rhodesiense can only be used in a level 3 containment lab. In addition, the T. b. brucei  genome 
has been sequenced and recombinant DNA technology is well advanced (gene replacement, 
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inducible/constitutive gene expression, RNAi etc) allowing investigation of potential drug mode 
of action. Such technology cannot be done by using T. b. rhodesiense. 
 
Table 3. Activity of recombinant TbNTR and TcNTR towards selected analogs of Table 1. 
 
 
NTR-overexpressing T. b. brucei were ca. 2- to 5-fold more sensitive to most of the tested 
compounds with 6 being the exception (Table 4).  However, there was no good correlation 
between TbNTR/TcNTR enzymatic activity and specific antitrypanosomal activity. This, 
coupled with the modest fold difference in susceptibility observed between cells expressing 
different levels of TbNTR in comparison to the larger changes noted when using other 
nitroheterocycles such as Nfx, indicates that this oxidoreductase may not be the only activator of 
the aryloxy-phenylamide prodrug within the parasite or that other factors (e.g. permeability into 
mitochondrion, compound stability and pharmacokinetic factors in general) may play a role in 




Table 4. Antimicrobial activity of selected nitrotriazoles against BSF of T. b. brucei 
 
 
2.2.6. TcCYP51 inhibition 
Azole-based scaffolds are effective inhibitors of the T. cruzi enzyme sterol 14α-demethylase, 
TcCYP51 [37]. In addition, aryloxybenzylimidazoles have been described as CYP51 inhibitors 
[15]. Therefore, in silico docking studies were performed by using the ligand binding pocket of 
the crystal structure of 4H6O sterole-14 demethylase and Glide docking protocols, to 
investigate whether or not the present compounds bind to the protein as the reference compound 





Table 5. Docking scores of compounds in Table 1 
and reference 15, in the ligand binding pocket of 
4H6O sterole-14 demethylase. The score is a 
function of –logKd.  
 
 
The 3-nitrotriazole-based aryloxyphenylamides 2-4 showed a higher docking score than the 
reference compound 15, whereas the more rigid 3-nitrotriazole-based biphenylamide 6 showed a 
similar docking score with 15. The rest of the compounds demonstrated docking scores lower 
than compound 15, with compound 5 (the des-nitro analog of 3) showing the lowest docking 
score (Table 5). Examples of docked poses for compounds 3 and 15 are given in Fig. 1, which 
Compound


















show coordination between the heme iron of the enzyme and the N4 or N3 of the nitrotriazole 






Fig. 1. Docked poses of compound 3 (top) and reference compound 15 (bottom). The 
distance (in Å) is shown between the iron atom of the heme and the N4 (top) or N3 (bottom) 
of the nitrotriazole and imidazole rings, respectively. 
 
A distance of 2.0 and 2.76 Å is shown between the iron atom and the corresponding nitrogen 
atom for compounds 3 and 15, respectively. The docking score seems to be affected primarily by 
the distance between the N4 of the nitrotriazole ring and the iron atom of the heme in the active 
site of the enzyme, whereas the orientation of the core group of each molecule can change 
significantly, making a SAR correlation much more complicated in this case.  
There was good correlation between anti-T. cruzi activity (IC50 values against T. cruzi) and 
docking score (Fig. 2), suggesting that at least for compounds 2-4 and 6 the antichagasic activity 
may be also related to T. cruzi CYP51 inhibition, an assumption than needs to be verified.   
 
 


































Fig. 2. Correlation between antichagasic activity and docking scores. 
 
2.2.7. In vivo antichagasic activity 
The most active compounds (3, 4 and 6) against T. cruzi in vitro were evaluated for in vivo anti-
chagasic activity by using an acute T. cruzi infected murine model. Bnz was used in parallel as a 
positive control. Groups of 5 mice/group were treated i.p. for 10 consecutive days with each 
compound, at 13 mg/kg/day. In our previous work with 3-nitrotriazole-based rigid amides we 
have seen in vivo antichagasic activity at daily doses of 15 mg/kg, therefore we decided to use a 
slightly lower dose for the present tested analogs which demonstrate in vitro anti-T. cruzi activity 
at low nM concentrations (Table 1). The mean ratio of parasite levels was calculated after 5 and 
10 days of treatment. The data are summarized in Fig. 3 and images are presented in Fig. 4.  
 
 
Fig. 3. In vivo evaluation of the antichagasic efficacy of compounds 3, 4, 6 and benznidazole in 
















Day 5/Day 1 
Day 10/ Day 1 
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for 10 consecutive days. Parasite ratios were calculated after 5 and 10 days of treatment. The P 
values between each treated group and control group were < 0.0001. Groups of 5 mice/group 
were used. 
 
Fig. 4.  Images from mice treated with vehicle or compounds 3 and 4 after 1, 5 and 10 days of 
treatment. 
All tested compounds weren’t toxic at the given dose and time-frame and all, including Bnz, 
reduced the parasite load to undetectable levels (Fig. 4) after 5 days of treatment with statistical 
significance (p < 0.0001).  
 
3. Conclusions: 
3-Nitrotriazole-based aryloxyphenylamides are very potent and selective anti-T. cruzi agents 
both in vitro and in vivo, being able to reduce the parasite load to undetectable limits after just 5 
days of treatment of infected mice, at the very small i.p. dose of 13 mg/kg/day (Figures 3 and 4). 
Vehicle                 Comp. 3                   Comp. 4
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In addition, limited ADMET studies demonstrated that these compounds are metabolically stable 
and have a very good Caco-2 permeability, suggesting a favorable profile regarding oral 
administration (an example is given in the Supplementary material).  However, since activity in 
the acute model is not predictive for efficacy in chronic indeterminate Chagas patients, future 
experiments in a chronic murine model will be necessary to validate these agents for human use. 
Additionally, 2-nitro-imidazole-based aryloxyphenylamides demonstrated promising and 
selective antileishmanial properties in the macrophage model (which is more appropriate for 
drug screening) exhibiting IC50 values similar or better than pentostam (36). Therefore, this 
scaffold should be further explored for lead drug optimization.  
Both types of compounds act as substrates for trypanosomal type I NTR, whereas the 3-
nitrotriazole-based analogs demonstrated slightly better docking scores for 4H6O sterol-14 
demethylase than the reference compound 15, suggesting that the antichagasic properties of these 
compounds may be partially attributed to T. cruzi CYP51 inhibition, but this needs to be 
confirmed with enzymatic studies.  
Finally, although the present compounds should be evaluated for mutagenicity/genotoxicity 
due to their nitro group, it is worth mentioning that previous studies have shown that 3-
nitrotriazole-based amides are not mutagenic compared to their 2-nitroimidazole-based analogs 
[26], and do not cause developmental toxicity in zebrafish [28]. Therefore, 3-nitrotriazole-based 
aryloxyphenylamides constitute a new generation of potentially effective and more affordable 







All starting materials and solvents were purchased from Sigma-Aldrich (Milwaukee, WI), were 
of research-grade quality and used without further purification. Solvents used were anhydrous 
and the reactions were carried out under a nitrogen atmosphere and exclusion of moisture.  
Melting points were determined by using a Mel-Temp II Laboratory Devices apparatus 
(Holliston, MA) and are uncorrected. Proton NMR spectra were obtained on a Varian Inova-500 
or an Agilent Hg-400 spectrometer at 500 or 400 MHz, respectively, and are referenced to Me4Si 
or to the corresponding solvent, if the solvent was not CDCl3. High-resolution electrospray 
ionization (HRESIMS) mass spectra were obtained on a Agilent 6210 LC-TOF mass 
spectrometer at 11000 resolution.  Thin-layer chromatography was carried out on aluminum 
oxide N/UV254 or polygram silica gel G/UV254 coated plates (0.2 mm, Analtech, Newark, DE). 
Chromatography was carried out on preparative TLC alumina GF (1000 microns) or silica gel 
GF (1500 microns) plates (Analtech). All compounds were purified by preparative TLC 
chromatography on silica gel or alumina plates and also checked by HPLC (Agilent 1100) 
coupled to mass spectrometry (MS) and ultraviolet (UV) absorbance detectors. Purity was 
determined by comparing the area under the curve of the test compound peak to the combined 
areas of all peaks in the chromatogram, excluding DMSO and any peaks appearing in blank runs. 
Priority reporting was given to the UV traces (since mass spectrometer response can vary widely 
depending on a given compound’s ease of ionization). Purity of compounds lacking UV activity 
was reported using mass spectrometry detection.  Purity was ≥ 95% purity for all analogs.   
 
4.1.2. Synthesis of chlorides 1a-h: 
Some of the chlorides 1a-h are known in the literature and others are unknown or known through 
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chemical libraries but without any reference. The synthesis and spectroscopic data of 1a-h are 
provided in the supporting material. 
 
4.1.3. General Synthetic Procedure of amides 2-14:  
The potassium salt of 3-nitro-1,2,4-triazole or 2-nitroimidazole or 1,2,4-triazole (1 eq) was formed in 
CH3CN (6-10 mL), by refluxing with KOH (1.2 eq) for 30 min. To this suspension, 1a-h (1.1 eq) was 
added and the reaction mixture was refluxed under a nitrogen atmosphere for 9 h. In certain cases, 1a-h 
was added in CH3CN solution. The reaction mixture was checked by TLC for completion of the reaction 
and the solvent was evaporated. The residue was dissolved in ethyl acetate and the inorganic salts were 
filtered away. Upon preparative TLC (silica gel or alumina, depending on the mobility of the major band; 
ethyl acetate-petroleum ether), the desired product was obtained usually as a powder. Purity was checked 
also by HPLC and it was > 95%.   
 
4.1.3.1. 2-(3-nitro-1H-1,2,4-triazol-1-yl)-N-(4-phenoxyphenyl]acetamide (2): Off white 




H NMR (500 MHz, (CD3OD) δ: 8.70 (s, 1H), 7.56 (d, J 
= 9.5 Hz, 2H), 7.34 (t, J = 8.0 Hz, 2H), 7.09 (t, J = 8.0 Hz, 1H), 6.97 (d, J = 9.0 Hz, 4H), 5.28 (s, 2H). 
HRESIMS calcd for C16H13N5NaO4 m/z [M+Na]
+  
362.0860 found 362.0863.  
 
4.1.3.2. N-[4-(4-chlorophenoxy)phenyl]-2-(3-nitro-1H-1,2,4-triazol-1-yl)acetamide (3): White 




H NMR (500 MHz, (CD3OD) δ: 8.70 (s, 1H), 7.58 (d, J = 
9.5 Hz, 2H), 7.32 (d, J = 9.0 Hz, 2H), 7.00 (d, J = 9.0 Hz, 2H), 6.95 (d, J = 9.0 Hz, 2H), 5.29 (s, 2H).  
HRESIMS calcd for C16H12ClN5NaO4 m/z [M+Na]
+  
396.0475, 397.0527, 398.0512, 399.0514 found 




4.1.3.3. N-[4-(4-fluorophenoxy)phenyl]-2-(3-nitro-1H-1,2,4-triazol-1-yl)acetamide (4): Off white 




H NMR (500 MHz, (CD3COCD3) δ: 9.68 (br s, 1H), 8.73 (s, 1H), 
7.63 (d, J = 9.5 Hz, 2H), 7.14 (t, J = 9.0 Hz, 2H), 7.04 (m, 2H), 6.98 (d, J = 9.0 Hz, 2H), 5.40 (s, 2H). 
HRESIMS calcd for C16H12FN5NaO4 m/z [M+Na]
+  
380.0766 , 381.0793, found 380.0767, 381.0791. 
 
4.1.3.4. N-[4-(4-chlorophenoxy)phenyl]-2-(1H-1,2,4-triazol-1-yl)acetamide (5): Off white powder 




H NMR (500 MHz, (CClD3) δ: 8.32 (br s, 1H), 8.26 (s, 1H), 8.14 (s, 1H), 7.44 
(d, J = 8.5 Hz, 2H), 7.28 (d, J = 9.5 Hz, 2H), 6.97 (d, J = 9.5 Hz, 2H), 6.91 (d, J = 9.0 Hz, 2H), 5.02 (s, 





331.0776 and 351.0619, 353.0595 found 329.0804, 331.0784 and 351.0629, 353.060. 
 





H NMR (400 MHz, CD3COCD3) δ: 9.77 (br s, 1H), 8.75 (s, 1H), 7.99 (s, 1H), 





324.10912 and 346.0911, found 324.1099 and 346.0915. 
 
4.1.3.6. 2-(3-nitro-1H-1,2,4-triazol-1-yl)-N-(4-phenylpyrimidin-2-yl)acetamide (8): Off white powder (55 




H NMR (400 MHz, (CD3COCD3) δ: 10.04 (br s, 1 H), 8.74 (d, J = 5.2 Hz, 
1H), 8.73 (s, 1H), 8.26 (dd, J = 8.4, 1.2 Hz, 2H), 7.77 (d, J = 5.2 Hz, 1H), 7.58-7.53 (m, 3H), 6.03 (s, 2H). 
HRESIMS calcd for C14H12N7O3 m/z [M+H]
+  
326.0996, found 326.0995.  
 
4.1.3.7. N-(4-benzylphenyl)-2-(3-nitro-1H-1,2,4-triazol-1-yl)acetamide (9): White microcrystallic 




H NMR (400 MHz, (CD3COCD3) δ: 8.72 (s, 1H), 7.55 (dd, J = 8.8, 0.8 














H NMR (400 MHz, (CD3COCD3) δ: 9.67 (br s, 1 H), 8.73 (s, 1H), 7.55-7.30 (m, 6H), 
7.24 (t, J = 8.0 Hz, 1H), 7.14 (dd, J = 8.0, 1.6 Hz, 1H), 6.79 (dd, J = 8.0, 1.5 Hz, 1H), 5.40 (s, 2H), 5.10 
(s, 2H). HRESIMS calcd for C17H16N5O4 m/z [M+H]
+  
354.1197, found 354.1195.  
 
4.1.3.9. N-(1-benzylpiperidin-4-yl)-2-(3-nitro-1H-1,2,4-triazol-1-yl)acetamide (11): White 




H NMR (400 MHz, (CClD3) δ: 8.37 (s, 1H), 7.33-
7.24 (m, 5H), 5.83 (br d, J = 8.0 Hz, 1H), 4.92 (s, 2H), 3.83 (m, 1H), 3.49 (s, 2H), 2.81 (d, J = 11.6 Hz, 
2H), 2.12 (t, J = 11.2 Hz, 2H), 1.91 (d, J = 9.6 Hz, 2H), 1.50 (m, 2H).  HRESIMS calcd for C16H21N6O3 
m/z [M+H]
+
 345.1670 found 345.1677. 
 
4.1.3.10. 2-(2-nitro-1H-imidazol-1-yl)-N-(4-phenoxyphenyl]acetamide (12): Off white powder 




H NMR (500 MHz, (CClD3+ 1 drop of  acetone -6d) δ: 8.97 (br s, 1H), 7.45 (d, J 
= 9.5 Hz, 2H), 7.27 (t, J = 7.5 Hz, 2H), 7.19 (s, 1H), 7.16 (s, 1H), 7.03 (t, J = 7.5 Hz, 1H), 6.90 (dd, J = 





338.1015 and 361.0907, found 338.0974 and 361.0915.  
 
4.1.3.11. N-[4-(4-chlorophenoxy)phenyl]-2-(2-nitro-1H-imidazol-1-yl)acetamide (13): White 




H NMR (500 MHz, (CD3OD) δ: 7.55 (d, J = 9.0 Hz, 
2H), 7.50 (d,  J = 1.0 Hz, 1H), 7.32 (d, J = 9.5 Hz, 2H), 7.20 (d, J = 0.5 Hz, 1H), 6.98 (d, J = 9.0 Hz, 2H), 









4.1.3.12. N-[4-(4-fluorophenoxy)phenyl]-2-(2-nitro-1H-imidazol-1-yl)acetamide  (14): Off white powder 




H NMR (500 MHz, (CD3OD) δ: 7.52 (d, J = 8.5 Hz, 2H), 7.50 (d, J = 1.0 
Hz, 1H), 7.20 (d, J = 1.5 Hz, 1H), 7.08 (t, J = 8.5 Hz, 2H), 6.99 (dd, J = 9.5, 5.0 Hz, 2H), 6.95 (d, J = 9.5 
Hz, 2H), 5.34 (s, 2H). HRESIMS calcd for C17H13FN4NaO4 m/z [M+Na]
+  
379.0813, found 379.0821.  
 
4.2. Biological evaluation.  
4.2.1. In vitro screening: 
In vitro activity against T. cruzi, T. b. rhodesiense, L. donovani and cytotoxicity assessment 
using L6 cells (rat skeletal myoblasts) was determined using a 96-well plate format as previously 
described [38]. Data were analyzed with the graphic program Softmax Pro (Molecular Devices, 
Sunnyvale, CA, USA), which calculated IC50 values by linear regression from the sigmoidal dose 
inhibition curves. 
4.2.2. Activity against Leishmania donovani intracellular amastigotes; macrophage assay: 
Mouse peritoneal macrophages (4 x 10
4
 in 100 µL RPMI 1640 medium with 10% heat-
inactivated FBS) were seeded into wells of Lab-tek 16-chamber slides. After 24 hrs 1.2 x 10
5
 
amastigote Leishmania donovani in 100 µL were added. The amastigotes were taken from an 
axenic amastigote culture grown at pH 5.4. Four hrs later the medium containing free amastigote 
forms was removed and replaced by fresh medium. Next day the medium was replaced by 
medium containing different compound dilutions. Parasite growth in the presence of the drug 
was compared to control wells. After 96 hours of incubation the medium was removed and the 
slides fixed with methanol for 10 min followed by a staining with a 10% Giemsa solution. 
Infected and non-infected macrophages were counted for the control cultures and the ones 
exposed to the serial drug dilutions. The infection rates were determined. The results were 
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expressed as % reduction in parasite burden compared to control wells, and the IC50 calculated 
by linear regression analysis [39]. 
 
4.2.3. In vitro T. brucei brucei antiproliferating assays and susceptibility studies.   




 in 200 µL of growth medium containing 
different concentrations of  nitroheterocycle. Where appropriate, induction of the TbNTR was carried out 
by adding tetracycline (1 µg/mL). After incubation for 3 days at 37 
o
C, 20 µL of Alamar blue was added 
to each well and the plates incubated for a further 16 h. The cell density of each culture was determined as 
described before [29] and the IC50 established. 
 
4.2.4. Enzymatic activity studies with Type I NTRs.  
Recombinant TbNTR and TcNTR were prepared and assayed as previously described [40, 41]. The 
specific activity of purified his-tagged TbNTR was assessed spectrophotometrically at 340 nm using 





 of enzyme.  
 
4.2.5. Molecular Modeling studies: Docking into the active site of 4H6O sterole-14 alpha 
demethylase.  
The crystal structure of CYP51 (4H6O.pdb) which is available in protein database was imported 
for the analysis and found to be suitable for the docking experiments as there are no missing 
atoms found in the active site pocket of the enzyme. Moreover, the “b” values of the atoms are 
well within the average value of the crystal structure. 4H6O.pdb was validated with MolProbity 
[42] and the structure optimized by using Schrodinger software
 
(Schrodinger LLC, Version 9.2 , 
2014, New York). A MolProbity score of 1.5 (90
th
 percentile; N=5412, 2.70Å ± 0.25Å) was 
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obtained. MolProbity score combines the clashscore, rotamer, and Ramachandran evaluations 
into a single score, normalized to be on the same scale as X-ray resolution. 
Next, the Ligand Binding Site (LBS) of the protein was prepared. The 4H6O.pdb is a co-
crystal structure, therefore the bound ligand (reference compound) present in the active site of 
the CYP51 structure was extracted out, to visualize the binding pocket.  Using the LigPrep tools, 
3-D low energetic conformer of each compound was generated at pH = 7.4 ±1, retaining the 
absolute chirality of the compounds.   
Docking of the reference compound was carried out in the Glide-XP (extra precision) module 
of the Schrodinger software (Glide Docking Tools, Schrodinger Inc, 2014, NY) and the docked 
and crystal poses were compared. The RMSD between the two conformers was found to be < 1.5 
Å, which validates our docking protocols. Using the same protocols, all other compounds were 
docked into the active site pocket of CYP51, the binding poses were visualized and the Glide 
scores were collected. In order to cross check the binding poses, we used another docking 
engine, the Surflex dock tool implemented in SYBYLx1.3 (Sybylx 1.3, Tripos International, 
St.Louis, MO, 2013).
 
 Both the Glide and Surflex docking engines generated similar binding 
poses. 
 
4.2.6. In vivo antichagasic activity assessment of selected compounds: 
For in vivo studies, a Brazilian strain trypomastigotes from transgenic T. cruzi parasites 
expressing firefly luciferase were used as described before [26]. Briefly, parasites were injected 
in Balb/c mice (10
5
 trypomastigotes per mouse) and three days later mice were anesthesized by 
inhalation of isofluorane, followed by an injection with 150 mg/kg of D-luciferin potassium-salt 
in PBS. Mice were imaged 5 to 10 min after injection of luciferin with an IVIS 100 (Xenogen, 
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Alameda, CA) and the data acquisition and analysis were performed with the software 
LivingImage (Xenogen) as described before [43]. Treatment with test compounds was started 4 
days after infection at 13 mg/kg/day x 10 days, given i.p. The vehicle control was 2% 
methylcellulose + 0.5% Tween 80  and groups of 5 mice/group were used. Mice were imaged 
after 5 and 10 days of treatment. The ratio of parasite levels was calculated for each animal 
dividing the luciferase signal after treatment by the luciferase signal on the first imaging (before 
treatment). Mean values of all animals in each group  SD were used for plotting. 
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